CLK1 and early-onset autosomal dominant Alzheimer disease: Some SRPK/CLK inhibitors generate aberrant alternative splicing that protects against Duchenne muscular dystrophy by promoting a splice event that skips an inherited deleterious mutation (96), whereas other CLK inhibitors may protect against exon-skipping mutations in Alzheimer’s disease (97).